Important Safety Information on AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Thrombosis with Thrombocytopenia  – AstraZeneca Canada Inc. and Verity Pharmaceuticals Inc.

The AstraZeneca COVID-19 Vaccine and COVISHIELD were authorized for use in Canada on February 26, 2021, in accordance with the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports in Europe of thrombosis with thrombocytopenia following administration of the AstraZeneca COVID-19 Vaccine. Health Canada is working with international regulators and public health authorities to review data and evidence as it becomes available on these very rare events.